Comparing Daratumumab, pomalidomide, and dexamethasone in relapsed refractory multiple myeloma with contemporary clinical trials identifying the most appropriate patient population for the regimen
Latest Information Update: 28 Jul 2021
At a glance
- Drugs Daratumumab (Primary) ; Dexamethasone (Primary) ; Pomalidomide (Primary)
- Indications Multiple myeloma
- Focus Therapeutic Use
- 28 Jul 2021 New trial record
- 08 Jun 2021 Results presented at the 57th Annual Meeting of the American Society of Clinical Oncology